Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Mitsuharu Ueda et al.|New England Journal of Medicine|2018Cited by 2.9k
Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisTeresa Coelho, Ole B. Suhr, David Adams et al.|New England Journal of Medicine|2013Cited by 961